Hall Jesse Wayne 4

What Happened

• Jesse Wayne Hall, Chief Medical Officer of Aclaris Therapeutics (ACRS), had 36,375 restricted stock units (RSUs convert/vest) on May 1, 2026. The issuer converted those RSUs into shares and withheld 9,330 shares to cover tax withholding obligations (sale/withholding), valued at $4.41 per share for a withholding amount of $41,145. Net shares delivered to Hall after withholding were 27,045.

Key Details

• Transaction date: May 1, 2026; Form 4 filed May 5, 2026 (filed within the typical two-business-day window).
• Conversion/derivative entries: 36,375 RSUs converted to common shares (reported as derivative exercise/conversion, code M).
• Tax withholding: 9,330 shares withheld and disposed (code F) at $4.41/share for $41,145.
• Net shares received by the reporting person: 36,375 − 9,330 = 27,045 shares.
• Shares owned after the transaction: not disclosed in the provided filing details.
• Relevant footnotes: F1 — each RSU equals one contingent share; F2 — issuer withheld shares to satisfy tax withholding; F3 — these RSUs vest in four equal annual installments beginning May 1, 2025 (this was the first installment).

Context

• This was a vesting/settlement of RSUs, not an open-market purchase or voluntary sale. Withholding shares to pay taxes is routine and is similar to a “sell-to-cover” — it does not necessarily signal insider views on the company’s stock.
• For RSU awards, the material event is the vesting schedule (here, four annual installments). Purchases by insiders are generally more informative about confidence; vesting and withholding are compensation mechanics.